[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642260":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":61,"collaborators":64,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":26,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early Hypertonic Saline Initiation","EXPERIMENTAL","Participants receive nebulized 3% hypertonic saline (5 mL once daily via mesh nebulizer) for 6 months in addition to standard clinical care. Anti-NTM antibiotic treatment may be initiated at the discretion of the treating physician according to clinical indications.",[13],"Drug: Nebulized 3% Hypertonic Saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Delayed Hypertonic Saline Initiation","ACTIVE_COMPARATOR","Participants receive nebulized normal saline (5 mL once daily via mesh nebulizer) during Months 0-3, followed by nebulized 3% hypertonic saline during Months 4-6, in addition to standard clinical care. Anti-NTM antibiotic treatment may be initiated at the discretion of the treating physician according to clinical indications.",[13,19],"Drug: Nebulized Normal Saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Nebulized 3% Hypertonic Saline","Nebulized 3% hypertonic saline, 5 mL once daily via mesh nebulizer. Administered during Months 0-6 in the early-initiation arm and during Months 4-6 in the delayed-initiation arm after completion of the Month 3 assessment.",[15,9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Nebulized Normal Saline","Nebulized 0.9% normal saline, 5 mL once daily via mesh nebulizer during Months 0-3 in the delayed-initiation arm.",[15],[32],{"name":33,"affiliation":5,"role":34},"Sheng-Wei Pan, MD, PhD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+886-2-28717456","swpan2@vghtpe.gov.tw",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Jia-Yih Feng, MD, PhD","+886-2-28712121","jyfeng@vghtpe.gov.tw",[45],{"facility":46,"status":47,"city":48,"state":26,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Taipei Veterans General Hospital","RECRUITING","Taipei","11217","Taiwan","TW",{"type":53,"coordinates":54},"Point",[55,56],121.52639,25.05306,{"lat":56,"lon":55},[59],{"name":33,"role":37,"phone":60,"phoneExt":26,"email":39},"+886-2-28757456",{"type":34,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Sheng-Wei Pan","Attending Physician, Department of Chest Medicine, Taipei Veterans General Hospital",[65],{"name":66,"class":6},"National Science and Technology Council, Taiwan","100642260","hypertonic-saline-inhalation-for-nontuberculous-mycobacterial-lung-disease-100642260",false,"NCT07647575","Hypertonic Saline Inhalation for Nontuberculous Mycobacterial Lung Disease","A Randomized Controlled Trial of Early Versus Delayed Hypertonic Saline Inhalation in Treatment-Naïve Nontuberculous Mycobacterial Lung Disease","HiNTM","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Diagnosis of nontuberculous mycobacterial lung disease (NTM-LD) according to ATS\u002FERS\u002FESCMID\u002FIDSA diagnostic criteria, including compatible clinical symptoms, radiographic findings, and microbiological evidence.\n3. Not receiving anti-NTM antibiotic treatment at the time of screening.\n4. Able and willing to provide written informed consent.\n5. Able to perform nebulized inhalation therapy using a mesh nebulizer at home.\n\nExclusion Criteria:\n\n1. Active tuberculosis.\n2. Human immunodeficiency virus (HIV) infection.\n3. Receiving active treatment for malignancy.\n4. Uncontrolled asthma.\n5. Frequent or clinically significant hemoptysis.\n6. History of intolerance, bronchospasm, or hypersensitivity during inhalation testing with hypertonic saline.\n7. Inability to prepare a mesh nebulizer or perform inhalation therapy at home.\n8. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study participation.","ALL","18 Years",{"count":78,"type":79},262,"ESTIMATED","INTERVENTIONAL",[82],"NA","This multicenter randomized controlled trial evaluates the clinical and microbiological effects of inhaled 3% hypertonic saline in treatment-naïve patients with nontuberculous mycobacterial lung disease (NTM-LD). Participants are randomized in a 1:1 ratio to either early initiation of 3% hypertonic saline for 6 months or delayed initiation consisting of normal saline inhalation during the first 3 months followed by 3% hypertonic saline during the subsequent 3 months.\n\nThe primary objective is to compare respiratory symptom improvement between hypertonic saline and normal saline at Month 3. Secondary objectives include evaluating sputum microbiological outcomes, radiographic changes, inflammatory markers, small airway function, treatment initiation, safety, and within-participant changes before and after switching from normal saline to hypertonic saline in the delayed-initiation arm.\n\nThe first participant was enrolled on October 3, 2025.",[85,86],"Nontuberculous Mycobacterial Lung Disease","Bronchiectasis",[88,89,85,86,90,91,92,93,94],"Hypertonic saline inhalation","Airway clearance therapy","Mycobacterium avium complex","Mycobacterium abscessus","Respiratory Severity Score","Nebulized Hypertonic Saline","NTM-LD","2026-06-10",{"date":97,"type":98},"2026-06-15","ACTUAL",{"date":100,"type":98},"2025-10-03",{"date":102,"type":79},"2028-07-31",{"name":5,"class":6},1]